Novonesis
384.40 DKK
+0.92 %
Less than 1K followers
NSIS B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Valuation
Income statement
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Novonesis
P/E
Median 2019-2025
EV/S
Median 2019-2025
EV/EBIT
Median 2019-2025
Dividend yield
Median 2019-2025
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (DKK) | 326.00 | 349.50 | 537.20 | 351.90 | 371.10 | 407.70 | 407.80 |
| Shares | 287.6 | 282.0 | 277.9 | 276.6 | 281.0 | 468.3 | 468.3 |
| Market cap | 93,757.6 | 98,559.0 | 149,298.1 | 97,335.5 | 104,279.1 | 190,925.4 | 190,972.2 |
| Enterprise value | 97,806.6 | 102,430.0 | 154,523.1 | 103,142.5 | 110,944.1 | 202,237.3 | 211,361.4 |
| EV/S | 6.8 | 7.3 | 10.3 | 5.9 | 6.2 | 7.1 | 6.8 |
| EV/EBITDA | 18.7 | 20.8 | 28.5 | 17.1 | 20.7 | 20.9 | 18.3 |
| EV/EBIT | 24.2 | 28.0 | 38.6 | 22.6 | 27.9 | 54.1 | 34.7 |
| P/E | 29.7 | 34.9 | 47.5 | 26.5 | 34.0 | 81.6 | 43.7 |
| P/B | 8.17 | 8.77 | 12.23 | 6.84 | 7.27 | 2.29 | 2.36 |
| P/S | 6.5 | 7.0 | 10.0 | 5.5 | 5.8 | 6.7 | 6.2 |
| Dividend yield | 1.6 % | 1.5 % | 1.0 % | 1.7 % | 1.7 % | 1.0 % | 1.0 % |
| Equity ratio | 56.2 % | 54.8 % | 49.3 % | 50.8 % | 50.5 % | 73.5 % | 66.4 % |
| Gearing ratio | 41.8 % | 41.8 % | 51.6 % | 48.1 % | 54.2 % | 16.1 % | 27.7 % |